 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- | linafexor (CS0159) / Cascade Pharma
Enrollment closed, Trial completion date: CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis) (clinicaltrials.gov) - Nov 19, 2024
P2, N=75, Active, not recruiting, Sponsor: Cascade Pharmaceuticals, Inc
Recruiting --> Active, not recruiting | Trial completion date: Oct 2024 --> Jul 2025
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, linafexor (CS0159) / Cascade Pharma
Enrollment open: Efficacy and Safety of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DM (clinicaltrials.gov) - Sep 19, 2024
P=N/A, N=60, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
Recruiting --> Active, not recruiting | Trial completion date: Oct 2024 --> Jul 2025 Not yet recruiting --> Recruiting
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, linafexor (CS0159) / Cascade Pharma
New trial: Efficacy and Safety of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DM (clinicaltrials.gov) - Jul 8, 2024
P=N/A, N=60, Not yet recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
- | linafexor (CS0159) / Cascade Pharma
Trial completion, Trial completion date, Trial primary completion date: Study of [14C]CS0159 in China Healthy Subjects (clinicaltrials.gov) - Nov 21, 2023
P1, N=6, Completed, Sponsor: Cascade Pharmaceuticals, Inc
Not yet recruiting --> Recruiting Not yet recruiting --> Completed | Trial completion date: Feb 2024 --> Nov 2023 | Trial primary completion date: Feb 2024 --> Nov 2023
- ||| linafexor (CS0159) / Cascade Pharma
Trial completion: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH (clinicaltrials.gov) - Nov 21, 2023
P2, N=99, Completed, Sponsor: Cascade Pharmaceuticals, Inc
Not yet recruiting --> Completed | Trial completion date: Feb 2024 --> Nov 2023 | Trial primary completion date: Feb 2024 --> Nov 2023 Active, not recruiting --> Completed
- | linafexor (CS0159) / Cascade Pharma
New P1 trial: Study of [14C]CS0159 in China Healthy Subjects (clinicaltrials.gov) - Oct 23, 2023
P1, N=6, Not yet recruiting, Sponsor: Cascade Pharmaceuticals, Inc
- | linafexor (CS0159) / Cascade Pharma
Enrollment open: CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis) (clinicaltrials.gov) - Sep 1, 2023
P2, N=75, Recruiting, Sponsor: Cascade Pharmaceuticals, Inc
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | linafexor (CS0159) / Cascade Pharma
Enrollment open: CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis) (clinicaltrials.gov) - Sep 1, 2023
P2, N=50, Recruiting, Sponsor: Cascade Pharmaceuticals, Inc
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || linafexor (CS0159) / Cascade Pharma
Enrollment closed, Trial completion date, Trial primary completion date: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH (clinicaltrials.gov) - Jul 27, 2023
P2, N=99, Active, not recruiting, Sponsor: Cascade Pharmaceuticals, Inc
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Mar 2024 --> Nov 2023 | Trial primary completion date: Mar 2024 --> Nov 2023
- | linafexor (CS0159) / Cascade Pharma
New P2 trial: CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis) (clinicaltrials.gov) - Jun 9, 2023
P2, N=75, Not yet recruiting, Sponsor: Cascade Pharmaceuticals, Inc
- | linafexor (CS0159) / Cascade Pharma
New P2 trial: CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis) (clinicaltrials.gov) - Jun 9, 2023
P2, N=50, Not yet recruiting, Sponsor: Cascade Pharmaceuticals, Inc
- | linafexor (CS0159) / Cascade Pharma
Trial completion, Trial completion date: Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS0159 in Chinese Healthy Subjects (clinicaltrials.gov) - May 3, 2023
P1, N=36, Completed, Sponsor: Cascade Pharmaceuticals, Inc
Recruiting --> Active, not recruiting | Trial completion date: Mar 2024 --> Nov 2023 | Trial primary completion date: Mar 2024 --> Nov 2023 Recruiting --> Completed | Trial completion date: Jul 2023 --> Mar 2023
- ||| linafexor (CS0159) / Cascade Pharma
Enrollment open: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH (clinicaltrials.gov) - Feb 21, 2023
P2, N=100, Recruiting, Sponsor: Cascade Pharmaceuticals, Inc
Recruiting --> Completed | Trial completion date: Jul 2023 --> Mar 2023 Not yet recruiting --> Recruiting
- | linafexor (CS0159) / Cascade Pharma
Enrollment open: Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS0159 in Chinese Healthy Subjects (clinicaltrials.gov) - Jan 3, 2023
P1, N=36, Recruiting, Sponsor: Cascade Pharmaceuticals, Inc
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | linafexor (CS0159) / Cascade Pharma
New P1 trial: Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS0159 in Chinese Healthy Subjects (clinicaltrials.gov) - Nov 22, 2022
P1, N=36, Not yet recruiting, Sponsor: Cascade Pharmaceuticals, Inc
- |||| linafexor (CS0159) / Cascade Pharma
New P2 trial: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH (clinicaltrials.gov) - Oct 24, 2022
P2, N=100, Not yet recruiting, Sponsor: Cascade Pharmaceuticals, Inc
- ||| linafexor (CS0159) / Cascade Pharma
Trial completion: Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159 (clinicaltrials.gov) - Oct 17, 2022
P1, N=79, Completed, Sponsor: Cascade Pharmaceuticals, Inc
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||| linafexor (CS0159) / Cascade Pharma
Enrollment open: Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159 (clinicaltrials.gov) - Nov 28, 2021
P1, N=80, Recruiting, Sponsor: Cascade Pharmaceuticals, Inc
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||| linafexor (CS0159) / Cascade Pharma
New P1 trial: Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159 (clinicaltrials.gov) - Oct 19, 2021
P1, N=80, Not yet recruiting, Sponsor: Cascade Pharmaceuticals, Inc